Join Growin Stock Community!

Zentalis pharmaceuticals, inc.ZNTL.US Overview

US StockHealthcare
(No presentation for ZNTL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ZNTL AI Insights

ZNTL Overall Performance

ZNTL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ZNTL Recent Performance

2.18%

Zentalis pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ZNTL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ZNTL Key Information

ZNTL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ZNTL Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Price of ZNTL

ZNTL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ZNTL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.07
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.76
PB Ratio
0.63
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
368.14%
Revenue Growth (YoY)
-200.00%
Profit Growth (YoY)
-200.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.07
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.76
PB Ratio
0.63
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
368.14%
Revenue Growth (YoY)
-200.00%
Profit Growth (YoY)
-200.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ZNTL's latest earnings report released?

    The most recent financial report for Zentalis pharmaceuticals, inc. (ZNTL) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZNTL's short-term business performance and financial health. For the latest updates on ZNTL's earnings releases, visit this page regularly.

  • How much cash does ZNTL have?

    At the end of the period, Zentalis pharmaceuticals, inc. (ZNTL) held Total Cash and Cash Equivalents of 41.7M, accounting for 0.13 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ZNTL's EPS continuing to grow?

    According to the past four quarterly reports, Zentalis pharmaceuticals, inc. (ZNTL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.37. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ZNTL?

    Zentalis pharmaceuticals, inc. (ZNTL)'s Free Cash Flow (FCF) for the period is -26.96M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 38.78% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.